Research programme: anti-cancer therapeutics - Saverna Therapeutics
Latest Information Update: 24 Aug 2021
At a glance
- Originator Saverna Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Aug 2021 Anti-cancer therapeutics - Saverna Therapeutics is available for licensing as of 24 Aug 2021. http://www.saverna.com/investors
- 24 Aug 2021 Early research in Cancer in Switzerland (PO) before August 2021 (Saverna Therapeutics pipeline, August 2021)